Plozasiran Injection 25 mg/0.5 mL Suppliers & Bulk Manufacturers
Available Forms: Pre-filled syringe (subcutaneous)
Available Strengths: 25 mg/0.5 mL
Reference Brands: Redemplo (Arrowhead Pharmaceuticals)
Category: Heart Disorder
Plozasiran (Redemplo, Arrowhead) is an siRNA medicine that lowers triglycerides by silencing APOC3. It is given as a subcutaneous injection every three months and was approved by the US FDA in November 2025 for familial chylomicronaemia syndrome. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.
Manufacture or export Plozasiran Injection? List it or send an offer →
Product Description:
Plozasiran is a small interfering RNA (siRNA) directed at the liver. It switches off production of apolipoprotein C-III (APOC3), a protein that blocks the breakdown of triglyceride-rich particles in the blood. With less APOC3, triglycerides fall sharply, including in people who lack working lipoprotein lipase.
The US FDA approved plozasiran as Redemplo in November 2025 to reduce triglycerides in adults with familial chylomicronaemia syndrome (FCS), a rare inherited disorder that causes extremely high triglycerides and repeated attacks of pancreatitis. It is used alongside a very low-fat diet. The dose is 25 mg by subcutaneous injection from a pre-filled syringe once every three months.
Sourcing and licensing notes. Plozasiran is patented and made only by Arrowhead; there is no generic. The other APOC3 medicine for FCS, olezarsen (Tryngolza), is also listed on PharmaTradz. We confirm registration status for each destination before quoting.
How Plozasiran Injection is supplied today, and licensing ahead of patent expiry
Where plozasiran is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Redemplo · FDA · Nov 2025 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Lowering triglycerides in adults with familial chylomicronaemia syndrome (FCS), together with a low-fat diet.
Redemplo, from Arrowhead Pharmaceuticals. The US FDA approved it in November 2025.
Once every three months, as a 25 mg injection under the skin.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Olezarsen Injection
Strength:
80 mg/0.8 mL
Form: Autoinjector (subcutaneous)
Reference Brands: Tryngolza (Ionis; Sobi outside the US)
View DetailsLerodalcibep Injection
Strength:
300 mg/1.2 mL
Form: Pre-filled syringe, autoinjector (subcutaneous)
Reference Brands: Lerochol (LIB Therapeutics)
View DetailsObicetrapib Tablets
Strength:
10 mg; 10 mg + ezetimibe 10 mg
Form: Tablets
Reference Brands: Ubeslo, Evlarco (with ezetimibe) — NewAmsterdam Pharma / Menarini
View DetailsEnlicitide Tablets
Strength:
20 mg
Form: Tablets
Reference Brands: Lipfendra (Merck & Co / MSD)
View Details
Dofetilide
Strength:
0.125mg, 0.25mg, 0.5mg
Form: Tablets
Reference Brands: Tikosyn (USA)
View Details
Felodipine
Strength:
2.5 mg, 5 mg, 10 mg
Form: Tablets
Reference Brands: Plendil (USA/ EU), Felodur (EU), Renedil (EU/UK)
View Details
Fosinopril Sodium
Strength:
10 mg, 20 mg, 40 mg
Form: Tablets
Reference Brands: Monopril (USA/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
